BIOLASE, Inc. (NASDAQ:BIOL) went up by 1.75% from its latest closing price compared to the recent 1-year high of $1.16. The company’s stock price has collected 7.74% of gains in the last five trading sessions.
Is It Worth Investing in BIOLASE, Inc. (NASDAQ :BIOL) Right Now?
BIOLASE, Inc. (NASDAQ:BIOL) scored a price-to-earnings ratio above its average ratio, recording 30.67 x from its present earnings ratio. Plus, the 36-month beta value for BIOL is at 1.79. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for BIOLASE, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $1.63, which is -$0.32 below the current price. BIOL currently public float of 83.94M and currently shorts hold a 0.61% ratio of that float. Today, the average trading volume of BIOL was 7.78M shares.
BIOL’s Market Performance
BIOL stocks went up by 7.74% for the week, with a monthly drop of -20.69% and a quarterly performance of -34.63%, while its annual performance rate touched -70.09%. The volatility ratio for the week stands at 11.18% while the volatility levels for the past 30 days are set at 9.26% for BIOLASE, Inc.. The simple moving average for the period of the last 20 days is -0.74% for BIOL stocks with a simple moving average of -35.62% for the last 200 days.
Analysts’ Opinion of BIOL
Many brokerage firms have already submitted their reports for BIOL stocks, with The Benchmark Company repeating the rating for BIOL by listing it as a “Speculative Buy.” The predicted price for BIOL in the upcoming period, according to The Benchmark Company is $2 based on the research report published on June 19th of the previous year 2019.
Singular Research, on the other hand, stated in their research note that they expect to see BIOL reach a price target of $2.50. The rating they have provided for BIOL stocks is “Buy” according to the report published on April 25th, 2017.
WallachBeth gave a rating of “ Hold” to BIOL, setting the target price at $2.50 in the report published on May 13th of the previous year.
BIOL Trading at -18.28% from the 50-Day Moving Average
After a stumble in the market that brought BIOL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.35% of loss for the given period.
Volatility was left at 9.26%, however, over the last 30 days, the volatility rate increased by 11.18%, as shares sank -20.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.63% lower at present.
During the last 5 trading sessions, BIOL rose by +7.74%, which changed the moving average for the period of 200-days by -45.31% in comparison to the 20-day moving average, which settled at $0.3182. In addition, BIOLASE, Inc. saw -42.10% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at BIOL starting from FEINBERG LARRY N, who sold 1,770,312 shares at the price of $0.55 back on Jun 09. After this action, FEINBERG LARRY N now owns 0 shares of BIOLASE, Inc., valued at $976,010 using the latest closing price.
FEINBERG LARRY N, the 10% Owner of BIOLASE, Inc., sold 3,402,938 shares at $0.55 during a trade that took place back on Jun 08, which means that FEINBERG LARRY N is holding 264,141 shares at $1,885,908 based on the most recent closing price.
Stock Fundamentals for BIOL
Current profitability levels for the company are sitting at:
- -41.33 for the present operating margin
- +37.80 for the gross margin
The net margin for BIOLASE, Inc. stands at -47.24. The total capital return value is set at -77.99, while invested capital returns managed to touch -135.93.
Based on BIOLASE, Inc. (BIOL), the company’s capital structure generated 317.64 points at debt to equity in total, while total debt to capital is 76.06. Total debt to assets is 42.09, with long-term debt to equity ratio resting at -7.24. Finally, the long-term debt to capital ratio is 0.80.
When we switch over and look at the enterprise to sales, we see a ratio of 0.65, with the company’s debt to enterprise value settled at 0.56. The receivables turnover for the company is 3.80 and the total asset turnover is 1.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.05.